![]() |
Diabetes patients can now gain freedom from bothersome and painful finger pricks for glucose self-monitoring as new Dexcom G6 CGM makes its way in European and US market. Dexcom, Inc. a leader in continuous glucose monitoring (CGM) announced on June 12, 2018, that it has received European approval (CE mark) to market its Dexcom G6 for people with diabetes ages two years and above.
Since it’s introduction nearly 4 decades ago, fingerstick blood glucose testing has been the cornerstone of diabetes self-management. But pricking your finger ten or more times a day is painful, cumbersome and requires a lot of paraphernalia.
Dexcom G6 is a breakthrough in the field of continuous glucose monitoring, especially for people who require insulin. It does not require a finger prick even for calibrating the system.
The G6 sensor has improved longevity of 10 days instead of 7 and the transmitter also got a new look with a reduction in size by 28%. People taking acetaminophen can also accurately monitor their blood glucose levels as the protective membrane over the sensor does not interfere with the readings.
The new Dexcom also comes with an auto-applicator that makes the sensor insertion simple and painless. Simply press the applicator with the patch onto your skin and press the orange button. The patch and sensor are ready to take the readings.
The Dexcom is syn with your iPhone, or any other smartphone device. For international users, the readings can also be displayed on a small touchscreen receiver. The receiver needs charging every 2 days and can be charged with micro-USB.
The receiver for the new G6 has not undergone much change, and users of G5 can upgrade the receiver by a simple software update.
Most people syn their G6 with a mobile device or Apple watch so that they are saved the hassle of carrying an additional device. The data can be shared with 5 additional people using the Dexcom Follow app or shared with your doctor using the Dexcom Clarity platform.
The Dexcom also alerts the user in event of blood sugar is trending toward 55 mg/dL in less than 20 minutes. This allows for ample time for the users to act.
This is the only CGM indicated for children ages 2 years and older.
It’s available for shipping to consumers in the US since early June.





